← Back to Search

Angiogenesis Inhibitor

GEN-1 + Chemo + Bevacizumab for Ovarian Cancer (MRD Trial)

Phase 1 & 2
Recruiting
Research Sponsored by Imunon
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if adding a new drug, IMNN-001, to standard cancer treatments can make the treatment more effective for patients. The standard treatments include chemotherapy and Bevacizumab, which are commonly used for various cancers such as colorectal, lung, and ovarian cancers.

Who is the study for?
This trial is for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer at FIGO stage III or IV. They must be recommended for neoadjuvant therapy and have high grade serous adenocarcinoma confirmed by laparoscopy. Participants need proper organ function, no severe illnesses including recent COVID-19, no hormonal cancer therapies within a week before the trial starts, and an ECOG performance status of 0-1. Women must not be pregnant or breastfeeding and agree to use contraception.
What is being tested?
The study tests adding IMNN-001 (GEN-1) to standard chemotherapy with Bevacizumab versus chemotherapy with Bevacizumab alone in patients with newly diagnosed advanced ovarian-related cancers. It's a phase I/II randomized open-label trial assessing safety, dosing efficacy, and biological activity.
What are the potential side effects?
Possible side effects include those common to chemotherapy such as nausea, fatigue, hair loss; Bevacizumab may cause high blood pressure or bleeding issues; GEN-1 related side effects are under investigation but could involve immune system reactions similar to other gene therapies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Minimal Residual Disease
Secondary study objectives
OS
PFS

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Chemotherapy + BEV + IMNN-001 (Experimental)Experimental Treatment4 Interventions
Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles repeated every 21 days. BEV 15 mg/kg IV administration will be included with each cycle except during the cycles around time of surgery. During maintenance, BEV will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV. IMNN-001 80 mg/m2 IP will be administered weekly beginning C1D15 and continue weekly through the last cycle of adjuvant therapy. At the conclusion of chemotherapy, GEN-1 will be administered every 21 days with BEV in subjects who are BRCA-/HRP until disease progression or unacceptable toxicity for up to an additional 18 cycles.
Group II: Chemotherapy + BEV (Control)Experimental Treatment3 Interventions
Chemotherapy (neoadjuvant and adjuvant): Paclitaxel 175 mg/m2 IV followed by carboplatin AUC 5-6 IV starting on C1D1. During the neoadjuvant period, there will be from 4 to 6 cycles (at the Investigator's discretion, having an additional C4+1 and C4+2) repeated every 21 days. BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Paclitaxel
2011
Completed Phase 4
~5450
IMNN-001
2015
Completed Phase 1
~20
Carboplatin
2014
Completed Phase 3
~6120
Bevacizumab
2013
Completed Phase 4
~5540

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ovarian cancer include chemotherapy and targeted therapies. Chemotherapy agents work by damaging the DNA of cancer cells or inhibiting their ability to divide, leading to cell death. Targeted therapies, such as bevacizumab, inhibit angiogenesis, which is the formation of new blood vessels that supply the tumor, thereby starving the cancer cells. The IMNN-001 trial combines these approaches, aiming to maximize the destruction of cancer cells while preventing tumor growth. Understanding these mechanisms helps patients appreciate how their treatments are designed to control cancer progression and improve survival rates.
Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid.Integrative network analysis identifies potential targets and drugs for ovarian cancer.Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Find a Location

Who is running the clinical trial?

Breakthrough Cancer ResearchUNKNOWN
1 Previous Clinical Trials
200 Total Patients Enrolled
Break Through Cancer FoundationUNKNOWN
ImunonLead Sponsor
15 Previous Clinical Trials
1,536 Total Patients Enrolled
Amir Jazaeri, MDStudy ChairUniversity of Texas MD Anderson Center
3 Previous Clinical Trials
102 Total Patients Enrolled
2 Trials studying Ovarian Cancer
71 Patients Enrolled for Ovarian Cancer

Media Library

Bevacizumab (Angiogenesis Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05739981 — Phase 1 & 2
Ovarian Cancer Research Study Groups: Chemotherapy + BEV + IMNN-001 (Experimental), Chemotherapy + BEV (Control)
Ovarian Cancer Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT05739981 — Phase 1 & 2
Bevacizumab (Angiogenesis Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05739981 — Phase 1 & 2
~24 spots leftby Aug 2026